Comparative hemodynamic effects of levosimendan alone and in conjunction with 4-aminopyridine or calcium chloride in a rodent model of severe verapamil poisoning.
Levosimendan (Levo) increases sensitivity of troponin-C to calcium, thus increasing myocardial contractility. It is also a vascular K+-ATP channel agonist producing peripheral vasodilation. Previous research with levosimendan revealed an increase in cardiac output (CO) but not blood pressure (BP) in experimental verapamil poisoning. Levosimendan's K+-channel agonist properties may augment verapamil's vasodilatory effects. 4-Aminopyridine (4-AP) is a K+-channel antagonist. It has successfully reversed hypotension in experimental verapamil poisoning. We hypothesized that coadministration of these agents may improve BP and CO in verapamil poisoning. Anesthetized, ventilated, and canulated male Wistar rats were poisoned with verapamil. Animals received one of six treatments, which are as follows: (1) n-saline infusion (control), (2) Levo 6.25 μg/kg loading dose and 36 μg/kg/h infusion, (3) 4-AP 2 mg/kg loading dose and infusion (4-AP), (4) Levo+4-AP, (5) CaCl₂ loading dose and infusion, and (6) Levo+CaCl(2). Hemodynamic parameters were recorded for 60 min. Outcome measures were changes in CO, BP, and heart rate (HR) compared to control. All groups had similar pretoxicity and peak toxicity CO (50% of pretoxicity value), BP (50% or pretoxicity value), and HR. Control group CO, BP, and HR progressively dropped during the verapamil infusion. Levosimendan produced a statistically significant improvement in CO (75% of pretoxicity level) but not BP in comparison to control. 4-AP produced a significant improvement in CO (110% of pretoxicity) and BP (78% of pretoxicity). Levo+4-AP and Levo+CaCl₂ groups improved CO (100% of pretoxicity) and BP (77% and 50% of pretoxicity, respectively), but there was no additive increase in CO or BP in animals compared to 4-AP or CaCl₂ alone. Levosimendan moderately improved CO but not BP in verapamil poisoning. The hypotensive effects of levosimendan were not overcome by coadministration of either 4-AP or CaCl₂. Levosimendan may not be an appropriate agent to use in the treatment of verapamil poisoning.
Graudins
Andis
A
Clinical and Experimental Toxicology Unit, Department of Emergency Medicine, Prince of Wales Hospital, Randwick, NSW, Australia. andis.graudins@monash.edu
Wong
Kathy Ka Ling
KK
D015761:4-Aminopyridine / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000506:poisoning*; D015220:Calcium Channels / Q000187:drug effects / Q000378:metabolism; D002122:Calcium Chloride / Q000494:pharmacology*; D002302:Cardiac Output / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006835:Hydrazones / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D026902:Potassium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D011724:Pyridazines / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D000077464:Simendan; D013534:Survival; D014665:Vasodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014700:Verapamil / Q000506:poisoning*
D002121:Calcium Channel Blockers; D015220:Calcium Channels; D006835:Hydrazones; D026902:Potassium Channel Blockers; D011724:Pyridazines; D014665:Vasodilator Agents; D000077464:Simendan; D015761:4-Aminopyridine; D014700:Verapamil; D002122:Calcium Chloride
Crit Care Med. 2005 Mar;33(3):487-91
15753736
J Clin Invest. 1986 Jun;77(6):1805-11
3011861
J Toxicol Clin Toxicol. 1998;36(4):301-7
9711195
J Clin Invest. 1984 May;73(5):1291-6
6538884
Am J Physiol. 1989 Aug;257(2 Pt 2):H571-80
2669529
J Cardiovasc Pharmacol. 1999 Aug;34(2):219-28
10445673
Med J Aust. 1993 Feb 1;158(3):202-4
8450791
Pol J Pharmacol. 2003 May-Jun;55(3):425-32
14506322
Ital Heart J. 2003 May;4 Suppl 2:34S-38S
14635368
Circulation. 2000 Oct 31;102(18):2222-7
11056096
Expert Opin Investig Drugs. 2001 May;10(5):955-70
11322869
J Lab Clin Med. 2005 Nov;146(5):256-61
16242524
Curr Heart Fail Rep. 2004 Sep;1(3):136-44
16036037
Lab Anim Sci. 1978 Apr;28(2):157-62
642434
J Toxicol Clin Toxicol. 1994;32(5):583-7
7932918
Clin Toxicol (Phila). 2008 Jan;46(1):50-6
17926153
Przegl Lek. 2003;60(4):271-3
14569901